Double maintains 2 strategies that include DNTH - Dianthus Therapeutics, Inc.
Yahoo
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company’s participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will hos
Yahoo
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe auto
Yahoo
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H’26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H’26
Yahoo
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as a self-administered autoinjector dosed once every two weeks NEW YORK and WALTHAM, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology com
Yahoo
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at two upcoming investor events. Baird Biotech Discovery Series - Marino Garcia, Chief Executive Officer, will participate in a fireside chat webcast on Tuesday, May 6 at 1:30 p.m. EDT.Bank of
SeekingAlpha
Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMNM | 50.65% | $763.10M | -27.52% | 0.00% |
SYRE | 47.05% | $918.58M | -35.26% | 0.00% |
XNCR | 47.02% | $579.33M | -57.00% | 0.00% |
CRNX | 46.93% | $2.81B | -33.11% | 0.00% |
IMVT | 46.30% | $2.75B | -39.02% | 0.00% |
IDYA | 46.01% | $1.87B | -39.13% | 0.00% |
RNA | 43.62% | $3.50B | -28.94% | 0.00% |
ACLX | 43.02% | $3.60B | +18.41% | 0.00% |
OCUL | 42.94% | $1.47B | +34.80% | 0.00% |
REPL | 42.91% | $719.22M | +3.67% | 0.00% |
BEAM | 42.34% | $1.69B | -28.30% | 0.00% |
RVMD | 42.13% | $6.88B | -4.90% | 0.00% |
COGT | 41.91% | $808.38M | -15.78% | 0.00% |
CRSP | 41.75% | $4.10B | -12.07% | 0.00% |
RXRX | 41.41% | $2.04B | -32.93% | 0.00% |
KRYS | 40.86% | $4.01B | -24.37% | 0.00% |
EYPT | 40.82% | $663.34M | +10.80% | 0.00% |
OVID | 40.82% | $21.48M | -60.74% | 0.00% |
DAWN | 40.77% | $655.81M | -53.05% | 0.00% |
DNLI | 40.65% | $2.05B | -39.28% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -28.77% | $99.76M | 0.59% |
VIXY | -28.23% | $165.69M | 0.85% |
BTAL | -22.01% | $296.79M | 1.43% |
ULST | -19.15% | $662.59M | 0.2% |
IVOL | -17.61% | $351.30M | 1.02% |
SPTS | -12.04% | $5.78B | 0.03% |
IBTH | -11.12% | $1.60B | 0.07% |
FTSD | -10.84% | $231.79M | 0.25% |
IBTG | -10.60% | $1.92B | 0.07% |
JMST | -9.86% | $4.06B | 0.18% |
UTWO | -8.92% | $379.36M | 0.15% |
UUP | -8.87% | $237.02M | 0.77% |
XHLF | -8.85% | $1.73B | 0.03% |
GBIL | -8.23% | $6.40B | 0.12% |
VGSH | -7.99% | $22.80B | 0.03% |
SHYM | -7.91% | $349.95M | 0.35% |
USDU | -7.52% | $162.92M | 0.5% |
LDUR | -7.15% | $929.55M | 0.5% |
SCHO | -6.81% | $11.46B | 0.03% |
XONE | -6.74% | $585.86M | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IEF | 0.04% | $34.98B | 0.15% |
CMBS | 0.12% | $445.85M | 0.25% |
SPSK | -0.16% | $316.15M | 0.5% |
AGZD | -0.22% | $102.66M | 0.23% |
DBE | -0.22% | $51.16M | 0.77% |
WEAT | -0.23% | $117.15M | 0.28% |
TIPX | 0.35% | $1.67B | 0.15% |
DFNM | -0.40% | $1.56B | 0.17% |
AGZ | -0.48% | $614.02M | 0.2% |
FLMI | 0.51% | $722.98M | 0.3% |
MLN | 0.58% | $539.58M | 0.24% |
FXY | -0.59% | $815.67M | 0.4% |
UCON | -0.59% | $2.98B | 0.86% |
FTSM | -0.63% | $6.40B | 0.45% |
ISTB | 0.67% | $4.45B | 0.06% |
IBDR | 0.67% | $3.33B | 0.1% |
LGOV | 0.70% | $708.16M | 0.67% |
BNO | 0.72% | $103.68M | 1% |
BIL | -0.94% | $42.87B | 0.1356% |
IBTO | -1.01% | $352.26M | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SO | -0.02% | $99.90B | +17.18% | 3.20% |
FRO | 0.05% | $3.78B | -34.08% | 8.06% |
AXON | -0.10% | $63.73B | +178.21% | 0.00% |
PODD | 0.14% | $22.03B | +55.14% | 0.00% |
BTCT | -0.22% | $18.98M | +37.85% | 0.00% |
CNP | 0.26% | $23.74B | +17.40% | 2.34% |
NEE | 0.36% | $145.94B | +0.11% | 3.18% |
AMCX | 0.38% | $286.64M | -33.95% | 0.00% |
HIHO | -0.42% | $7.53M | -17.39% | 4.00% |
ETR | -0.45% | $35.53B | +54.17% | 4.29% |
CTRE | 0.45% | $5.87B | +21.91% | 3.97% |
T | -0.52% | $202.05B | +46.94% | 3.95% |
CORT | -0.62% | $7.76B | +125.36% | 0.00% |
CNX | 0.63% | $4.89B | +39.05% | 0.00% |
MCK | 0.66% | $90.65B | +24.27% | 0.39% |
LFVN | 0.67% | $159.74M | +97.66% | 1.30% |
RTX | -0.70% | $193.26B | +44.10% | 1.77% |
RILY | -0.70% | $89.36M | -83.39% | 0.00% |
NOC | -0.74% | $71.10B | +13.32% | 1.72% |
ALHC | 0.74% | $2.74B | +77.11% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 56.12% | $4.95B | 0.35% |
IBB | 52.94% | $5.36B | 0.45% |
GNOM | 52.09% | $44.21M | 0.5% |
PBE | 46.58% | $223.16M | 0.58% |
ARKG | 45.76% | $1.05B | 0.75% |
BBH | 45.12% | $329.40M | 0.35% |
PINK | 44.25% | $133.06M | 0.5% |
FBT | 43.27% | $1.01B | 0.54% |
XPH | 42.98% | $149.79M | 0.35% |
PTH | 40.62% | $100.99M | 0.6% |
IWC | 39.43% | $824.65M | 0.6% |
IWO | 38.47% | $11.48B | 0.24% |
QQQJ | 38.26% | $613.07M | 0.15% |
RTH | 37.64% | $241.48M | 0.35% |
XT | 37.34% | $3.36B | 0.46% |
KJAN | 37.18% | $289.38M | 0.79% |
ISCG | 36.97% | $679.06M | 0.06% |
BALT | 36.90% | $1.49B | 0.69% |
PID | 36.83% | $831.47M | 0.53% |
VT | 36.81% | $47.94B | 0.06% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VHC | -12.47% | $45.90M | +59.26% | 0.00% |
CME | -9.31% | $99.01B | +39.76% | 3.87% |
PM | -7.26% | $281.78B | +78.65% | 3.00% |
LNT | -6.60% | $15.50B | +18.57% | 3.28% |
PRT | -6.44% | $51.58M | +9.00% | 10.33% |
STG | -5.76% | $29.06M | -28.79% | 0.00% |
PULM | -5.68% | $25.57M | +262.69% | 0.00% |
LITB | -5.26% | $21.70M | -78.27% | 0.00% |
AEP | -5.03% | $54.73B | +16.78% | 3.58% |
NEUE | -4.76% | $61.96M | +27.57% | 0.00% |
CBOE | -4.57% | $23.98B | +34.66% | 1.10% |
MSEX | -4.31% | $976.83M | +4.31% | 2.48% |
CMS | -4.24% | $20.64B | +15.92% | 3.07% |
AIFU | -4.24% | $6.13B | +82.50% | 0.00% |
EVRG | -4.05% | $15.72B | +28.96% | 3.88% |
ED | -3.88% | $35.36B | +9.76% | 3.39% |
ARRY | -3.65% | $982.40M | -37.23% | 0.00% |
TRVG | -3.64% | $82.60M | +79.60% | 0.00% |
AVA | -3.47% | $3.03B | +8.75% | 5.13% |
AWK | -3.13% | $26.90B | +6.78% | 2.27% |
Current Value
$17.631 Year Return
Current Value
$17.631 Year Return